Else Bijker
Postdoctoral researcher
Else is a paediatrician and postdoctoral researcher at the Oxford Vaccine Group, working on the Novel and Optimized Diagnostics in Pediatric Tuberculosis (NOD) and The Feasibility of Novel Diagnostics for TB in Endemic Countries Consortium (FEND) studies. She is also co-investigator for the Resilient Responses to Protect Lung Health in Nunavik project.
She studied medicine at Maastricht University, the Netherlands, where she graduated in 2009. She completed her PhD cum laude in 2015 at the department of Medical Microbiology of the Radboud University Medical Center in Nijmegen, the Netherlands (thesis: “Constructing protection and immune responses against malaria. Studies on whole sporozoite immunization approaches”). She is currently working as a fellow in paediatric infectious diseases and immunology at Maastricht UMC+.
Recent publications
-
Facilitators and barriers affecting the implementation of e-health for chronic respiratory diseases in remote settings: a qualitative evidence synthesis.
Salmi EM. et al, (2025), BMC Health Serv Res, 25
-
FujiLAM for the diagnosis of childhood tuberculosis: a systematic review.
Olbrich L. et al, (2022), BMJ Paediatr Open, 6
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891